NCT05597683 Quadratus Lumborum Block After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy
| NCT ID | NCT05597683 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Gangnam Severance Hospital |
| Condition | Cytoreductive Surgery |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2022-11-15 |
| Primary Completion | 2024-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2022-11-15 with a primary completion date of 2024-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to assess whether transmusculr quadratus lomborum block (QL block) can reduce postoperative pain after cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (CRS and HIPEC). Patients will be randomly assigned to either QL block group or control group. Ultrasound-guided bilateral transmuscular quadratus lomborum block will be performed in QL block group using 0.375% ropivacaine. Multimodal analgesic regimen including acetaminophen, nonsteroidal antiinflammatory drugs (NSAIDs), and rescue opioids will be used in every patient. Primary outcome is opioid consumption for 24 hours after surgery. Secondary outcomes included pain scores, time to first rescue analgesics, quality of recovery score, length of hospital stay.
Eligibility Criteria
Inclusion Criteria: \- Adult patients who are scheduled to undergo cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (CRS and HIPEC) Exclusion Criteria: 1. Allergy to local anesthetics or fentanyl 2. Chronic pain 3. Drug abuse 4. Patients who are unable to use patient-controlled analgesia 5. Skin infection at site for quadratus lomborum block 6. pregnant or breatfeeding women 7. Patients who are unable to communicate
Contact & Investigator
Young Song
PRINCIPAL INVESTIGATOR
Gangnam Severance Hospital
Frequently Asked Questions
Who can join the NCT05597683 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Cytoreductive Surgery. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05597683 currently recruiting?
Yes, NCT05597683 is actively recruiting participants. Contact the research team at mayskpark@yuhs.ac for enrollment information.
Where is the NCT05597683 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT05597683 clinical trial?
NCT05597683 is sponsored by Gangnam Severance Hospital. The principal investigator is Young Song at Gangnam Severance Hospital. The trial plans to enroll 50 participants.